Daily Briefing: Bad flu season getting worse

U.S. flu activity is surging during peak holiday travel, with New York reporting its highest single-week count for the week ending Dec. 20 — a 38% increase week-over-week — and officials warning of a potential vaccine mismatch alongside declining vaccination rates. Diplomatically, a meeting between President Trump and Ukrainian President Zelenskyy failed to resolve core territorial concession issues, leaving the peace process unsettled. In markets, AI-related equities continue to rally despite bubble concerns (Nvidia ~+36% and Alphabet ~+66% through Dec. 23), while privacy concerns over biometric access at borders and consumer-focused stories (gaming communities, fitness tie-ins) round out softer consumer and media themes.

Analysis

Market structure: A sharp flu surge benefits healthcare distributors (CVS, WBA), urgent care/telehealth providers and large vaccine makers (PFE, MRNA) through higher Rx/OTC and vaccine demand over the next 4–12 weeks, while travel & leisure (airlines, hotels) face immediate revenue headwinds during the holiday window. AI winners (NVDA, GOOGL) retain pricing power as momentum investors drive multiples higher despite valuation risk — expect continued concentration into mega-cap growth in equities and higher skew in single-stock options.

Risk assessment: Tail risks include a vaccine-mismatch driven hospitalization spike (low probability, high impact over 1–3 months) that could force travel restrictions and boost healthcare utilization, or abrupt regulatory action on AI/biometrics within 3–12 months. Hidden dependencies: lower flu-shot uptake magnifies seasonality, and weather-driven travel disruptions compound demand shocks; catalysts to watch are CDC efficacy updates, TSA travel data (weekly), NVDA earnings and any AI regulatory bill in next 60–180 days.

Trade implications: Prefer short-duration hedges on travel (4–8 week puts or pair shorts) and tactical longs in pharmacy/urgent-care for 1–3 month re-rating; for AI, use defined-risk bullish options (3–6 month call spreads on NVDA or long-dated LEAPS on GOOGL) to capture momentum while capping downside. Rotate 1–3% allocation from discretionary/leisure into defensive healthcare and selective tech option structures.

Contrarian angles: Consensus fears about an AI “bubble” understate momentum persistence — price-first adoption can continue for quarters; conversely markets likely underprice short-term operational disruption to airlines/hotels from a bad flu season. Privacy/border biometrics litigation is a slow burner (12–24 months) and creates tactical alpha in hardware/OS sentiment rather than fundamentals.

Key Decisions for Investors

• Establish a 2–3% long position in CVS (CVS) or WBA sized to portfolio risk over 1–3 months expecting +8–12% upside from increased OTC/vaccine throughput; set a stop-loss at -6% and trim at +10–12%.
• Open a tactical 4–8 week put-spread on major US airlines (e.g., buy 30-delta puts and sell 15-delta puts on DAL or AAL) sized 0.5–1% portfolio to profit from holiday travel weakness; target a 2x return, stop if IV collapses >40% or travel volumes normalize in 2 weeks.
• Deploy a defined-risk bull call spread on NVDA for 3–6 months (buy 60–90 day or 3–6 month ITM/ATM call, sell higher strike) allocating 1–2% to capture continued AI momentum while capping downside; reassess around earnings or if NVDA rallies >25% from entry.
• Implement a pair trade: long GOOGL (1–2%) vs short JETS ETF (1%) to capture secular ad/AI upside versus cyclical travel downside; rebalance after CDC weeklies or NVDA earnings; close if GOOGL underperforms by >8% relative to JETS in 30 days.